Shopping Cart

Your shopping cart is currently empty

MPTP

Name: MPTP
Brand: TargetMol
SKU: T206266
Price: 34 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Synonyms:

Catalog No. T206266 Copy Product Info

Purity: 98.49%

🥰Excellent

MPTP is a dopaminergic neurotoxic substance capable of penetrating the blood-brain barrier, commonly used to establish Parkinson's disease animal models. As an upstream precursor of MPP⁺, MPTP further mediates neuronal apoptosis.

Cas No. 28289-54-5

Pack Size	Price	USA Stock	Global Stock
10 mg	$34	-	In Stock
25 mg	$58	-	In Stock
50 mg	$87	-	In Stock
100 mg	$137	-	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:98.49%

Appearance:Solid

Color:Yellow

Resource Download

COA LCMS HNMR

Product Introduction

Bioactivity

Description	MPTP is a dopaminergic neurotoxic substance capable of penetrating the blood-brain barrier, commonly used to establish Parkinson's disease animal models. As an upstream precursor of MPP⁺, MPTP further mediates neuronal apoptosis.
In vitro	Methods: Mouse phrenic nerve‑diaphragm preparations were used as the research model. Preconditioning was performed with 50 mM 4‑phenylpyridine. The half‑maximal inhibitory concentration (IC₅₀) of MPTP and d‑tubocurarine on twitch amplitude was determined respectively, and the pharmacological differences before and after pretreatment were compared. Results: Following pretreatment with 50 mM 4‑phenylpyridine, the IC₅₀ of MPTP for inhibiting twitch amplitude decreased from 53 mM to 18 mM in mouse phrenic nerve‑diaphragm preparations; meanwhile, the IC₅₀ of d‑tubocurarine decreased from 0.7 mM to 0.3 mM. These Results: indicate that 4‑phenylpyridine markedly enhances the inhibitory activity of both drugs [2].
In vivo	Methods: An animal model of Parkinson’s disease was established using MPTP. Based on the characteristics of MPTP-induced neural injury, the pathological mechanisms underlying dopaminergic neuronal degeneration, mitochondrial dysfunction and neuroinflammation were explored. Meanwhile, the in vivo metabolic process of MPTP was determined, and the half-life of its metabolite MPP⁺ in ovine serum was analyzed. Results: MPTP is a classic modeling agent for establishing Parkinson’s disease animal models and can mimic naturally occurring neurodegenerative pathological changes. It is suitable for investigating the mechanisms related to dopaminergic neuronal damage, mitochondrial dysfunction and neuroinflammation. After entering the body, MPTP is rapidly metabolized into MPP⁺, which exhibits a half-life of approximately 6 days in ovine serum.

Chemical Properties

Molecular Weight	173.25
Formula	C₁₂H₁₅N
Cas No.	28289-54-5
Smiles	C=1C=CC(=CC1)C2=CCN(C)CC2

Storage & Solubility Information

Storage

Keep away from direct sunlight Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 40.00 mg/mL (230.88 mM), Sonication is recommended.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	5.7720 mL	28.8600 mL	57.7201 mL	288.6003 mL
5 mM	1.1544 mL	5.7720 mL	11.5440 mL	57.7201 mL
10 mM	0.5772 mL	2.8860 mL	5.7720 mL	28.8600 mL
20 mM	0.2886 mL	1.4430 mL	2.8860 mL	14.4300 mL
50 mM	0.1154 mL	0.5772 mL	1.1544 mL	5.7720 mL
100 mM	0.0577 mL	0.2886 mL	0.5772 mL	2.8860 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.